Table 5.

Serious AEs that led to the discontinuation of immunotherapy or death

Patient (No.)	Age	Gender	Smoking status (P‐Y)	Histology	PD‐L1 expression	Site of metastatic lesions	Agent	Initial response	AEs
1	62	F	Never	Adeno	Unknown	Pleura, Peritoneum	Nivolumab	Unevaluated	Uncontrolled ascites Skin rash
2	55	F	2.5	SqCC	High	Pleura	Nivolumab	PD	Uncontrolled pleural effusion Elevated liver enzyme
3	34	F	Never	Adeno	High	Pericardium	Pembrolizumab	PD	Uncontrolled pleural effusion Recurrent pericardial effusion
4	68	M	Never	Adeno	Unknown	Pleura	Nivolumab	Unevaluated	Death
5	55	M	15	SqCC	Unknown	Pericardium	Nivolumab	Unevaluated	Death

Adeno, adenocarcinoma; AEs, adverse events; PD, progressive disease; P‐Y, pack‐year; SqCC, squamous cell carcinoma.